Recurrence of malignancy is, despite the use of high dose chemo and/or radiotherapy followed by autologous stem cell rescue, the most frequent reason for treatment failure in metastatic breast cancer. In order to improve treatment results using immunology strategies, allogeneic transplantation is increasingly being tested as treatment for chemotherapy refractory metastatic disease. Since 1993 a total of 15 stem cell transplants using either syngeneic (n = 4) or HLA-identical sibling (n = 11) donors have been reported to the EBMT from countries including Spain, Italy, Germany, Austria, Belgium, Croatia and Hungary. Conditioning varied from STAMP V regimen to conventional busulfan/cyclophosphamid. Some of the patients received donor lymphocyte infusion for prophylaxis but also treatment of disease recurrence. Results confirm the presence of a graft versus tumor effect described earlier by Eibl et al (Blood 1996) and Ueno et al. (JCO 1998). On the basis of these results a pilot study investigating the feasibility of allogeneic SCT on 10 patients with solid tumors using a uniform conditioning regimen was lanced within the EBMT. The study is still open for interested centers. Transplantation of allogeneic hematopoietic progenitor cells provides the chance of cure for patients suffering from various malignant as well as inherited diseases. However, the transplant itself can cause significant morbidity and mortality. Graft-versus-host disease (GVHD) is induced by donor-derived immunocompetent T-cells which are activated in case of tissue damage in the host and whenever HLA-disparities between host and donor are present. Even though T-cell depletion in the graft reduces the risks for GVHD induction, this strategy is associated with the particular risk for relapse and graft failure. To escape from this dilemma, we initiated a clinical trial on the transplantation of T-cell depleted allografts followed by a delayed addback of donor-derived T-cells. So far, 10 healthy HLAidentical sibling donors were included into the study. They S6 got G-CSF to mobilize CD34+ cells for 5 consecutive days. Large volume leukaphereses were performed at days 4+5. MNC fractions were subject to CD34+ selection leading to a mean CD34+ content of 86% and a mean 3.6 log reduction of CD3+ T-cells. Ten patients were treated with CY/TBI. They received a median of 2.8 × 10E6 CD34+ cells/kg and a median of 5.7 × 10E4 CD3+ T-cells/kg which is below the assumed threshold for GVHD induction. Nevertheless, GVHD prophylaxis was given with CSA plus short course MTX in 2 pts and CSA only in the remaining 8 pts. Engraftment was fast (median 9 days for leukocytes, median 13 days for platelets) and no signs of GVHD occurred. At day +60 and while maintaining 50% of the initial CSA dose, 2 × 10E6/kg CD3+ donor cells were transfused in 6 pts. One patient succumbed to acute gut GVHD. Another one developed limited chronic GVHD of the skin, while the remaining 4 pts had no signs of GVHD so far. In summary, CD34+ selection that leads to a substantial T-cell depletion provides a fast engraftment with minimal risk for GVHD. However, the optimal dose, time point, and concommittent immunosuppression for a delayed add-back of T-cells remains to be determined.
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before G-CSF to 1.82 × 10 7 /l (0.31-6.62) on day 3 and 5.71 × 10 7 /l (1.21-16.90) on day 4. We collected PBPC from a 3 fold blood volume by apheresis on day 3 (median 17.0 l) and on day 4 (median 15.0 l) in the 1st series (n = 38). In the 2nd series (n = 33) we collected PBSC from a 4.5 fold blood volume (median 21.0 l) only on day 4. There were no significant differences of the amount of collected CD34 + cells and CFU-GM between the both groups. These data indicate that relatively low doses of G-CSF can mobilize sufficient numbers of progenitor cells. A single apheresis with a large volume (4.5 fold of blood volume) allowed the collection of the required number of stem cells (Ͼ4 × 10 6 CD34 + cells/kg) for allogeneic transplantation.
